2 Minutes with Joey - BSX Stock News cover art

2 Minutes with Joey - BSX Stock News

2 Minutes with Joey - BSX Stock News

By: 2 Minutes with Joey
Listen for free

LIMITED TIME OFFER

£0.99/mo for the first 3 months. Terms apply.
Two minutes with Joey on Boston Scientific (BSX) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.Copyright 2 Minutes with Joey Social Sciences
Episodes
  • BSX Today - Jul 27: Price Target Trimmed

    BSX Today - Jul 27: Price Target Trimmed
    Jul 27 2026
    Hey there! It’s Joey here, your go-to guy for stock talk. I’ve been in the investing game for a while, and today, we’re checking out Boston Scientific, or BSX for short. It was a green day, up about 4.4%. Not too shabby, right?

    So, what went down today? BSX had a solid bounce back after some rough days. It seems like folks were feeling a bit more optimistic after the earnings report came out, which showed their segments did better than expected. That’s always a good sign, right? But the mood shifted a bit with some news from Oppenheimer, who trimmed their price target for BSX from $90 to $85. That kind of news can make investors a little jittery, but it didn’t stop the stock from gaining today.

    Now, why did all this happen? Well, it looks like the stronger-than-expected earnings gave investors a glimmer of hope. They’re seeing some solid performance in certain segments, which is definitely a plus. But then the price target cut hit, and that’s usually a wake-up call for a lot of people. When analysts adjust their targets, it can send mixed signals, and that’s what happened here. Some were feeling bullish, while others were a bit spooked. Classic stock market vibes, ya know?

    Oh, and here’s a little tidbit: BSX has been on the radar because it's one of those stocks that, if you invested $100 fifteen years ago, you’d be looking at a pretty nice return today. That’s always a fun fact to throw around when talking about long-term investments.

    To wrap it up, BSX had a good day despite some mixed signals from analysts. Earnings are looking strong, but the trimmed price target has folks watching closely. Just remember, this is all for info and entertainment, so do your own research before jumping in.

    Catch you later!
    Show More Show Less
    2 mins
  • BSX Today - Jul 26: Earnings and Guidance Shifts

    BSX Today - Jul 26: Earnings and Guidance Shifts
    Jul 26 2026
    Hey there! It’s Joey here, your friendly investor buddy. Been in the game for a while, and today we’re talking about Boston Scientific. So, BSX had a green day, up about 1.5%. Not a massive jump, but hey, green is good!

    So, what went down? The stock saw some action today, mainly because of earnings news. They reported some segments that beat expectations, which is usually a good sign. But, hold up! They also cut their guidance for the rest of the year. That kinda stings, right? It’s like getting a sweet treat and then realizing it’s just a tiny piece.

    Now, why the mixed bag? The CEO got real at the Bernstein Conference, saying there were three unexpected factors that led to this guidance cut. You know how sometimes things just don’t go as planned? Yeah, that’s basically what happened here. Investors are a bit torn. The earnings were solid, but the lowered outlook has people hitting the brakes.

    Adding to the drama, there’s been some chatter about an FDA advisory related to their Transcarotid System. That’s definitely a hot topic and can make folks nervous. Regulatory stuff can be a real wild card for stocks, so it’s understandable if people are feeling a bit uneasy.

    Oh, and there’s also buzz about Boston Scientific acquiring Penumbra. That’s a big deal and could shake things up in a good way. Mergers and acquisitions can often bring new energy and opportunities, but it takes time to see how it plays out.

    In short, BSX had a bit of a rollercoaster day. Earnings were strong, but the guidance cut and FDA advisory are weighing on minds. Just keep an eye out for how they handle these challenges moving forward.

    Alright, that’s the scoop for today! Just remember, I’m here to share info and keep it fun, but this isn’t financial advice. Catch you later!
    Show More Show Less
    2 mins
  • BSX Today - Jul 25: Recall Scrutiny Looms

    BSX Today - Jul 25: Recall Scrutiny Looms
    Jul 25 2026
    Hey there! It’s Joey here, your friendly neighborhood investor, and I’m breaking down what went down with Boston Scientific today. So, BSX had a pretty solid day, up about 1.5%. Not too shabby, right?

    Now, let’s talk about what happened. The stock didn’t just cruise along; it actually outperformed some of its competitors. That’s always a good sign. But there’s a bit of drama brewing, too. The company is facing some scrutiny over a potential recall. Yeah, that one stung. When recalls pop up, it can shake things up in the stock world.

    So, what’s the deal with the recall? Apparently, the FDA is taking a closer look at their transcarotid system. It’s like when your buddy’s got a questionable snack in the fridge, and you’re just waiting for someone to call them out on it. Not the best vibe for investors, you know?

    On the flip side, there’s chatter about their upcoming Q2 earnings. Analysts are getting their magnifying glasses out, trying to figure out how BSX is really doing. It’s that classic mix of excitement and anxiety — earnings can make or break a stock.

    Oh, and just to throw this in there, some folks believe BSX might be undervalued by a good chunk. That’s always nice to hear, but with the recall news, it’s like a double-edged sword.

    So, to wrap it up, BSX had a decent day on the charts, but keep an eye on that recall situation. It’s a mixed bag out there, and you know how it goes — the stock world can be a wild ride. Just remember, I’m here for info and fun, not financial advice. Catch you later!
    Show More Show Less
    1 min
adbl_web_anon_alc_button_suppression_t1
No reviews yet